Sunshine Biopharma (SBFM) Depreciation Expense (2019 - 2025)
Sunshine Biopharma (SBFM) reported Depreciation Expense of -$56801.0 for Q4 2025, down 389.79% on a YoY basis from $19600.7 in Q4 2024, and down 159.28% quarter-over-quarter from $95821.0 in Q3 2025.
Sunshine Biopharma (SBFM) Depreciation Expense (2019 - 2025) Analysis & Trends
Sunshine Biopharma has reported Depreciation Expense for 7 years, with the latest figure at -$56801.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation Expense fell 389.79% year-over-year to -$56801.0; the trailing twelve-month figure through Dec 2025 stood at $176346.0 (up 20.36% YoY), and the FY2025 full-year result was $176346.0, up 20.36% from the prior year.
- Depreciation Expense for Q4 2025 stood at -$56801.0, down from $95821.0 in the prior quarter.
- The five-year high for Depreciation Expense was $95821.0 in Q3 2025, with the low at -$56801.0 in Q4 2025.
- Historically, Depreciation Expense has averaged $22749.3 across 5 years, with a median of $3904.0 in 2023.
- Annual changes were most pronounced in 2023 — Depreciation Expense surged 4616.1% — and 2024, when it slumped 397.05%.
- Sunshine Biopharma's Depreciation Expense stood at $3184.0 in 2021, then surged by 353.99% to $14455.0 in 2022, then plunged by 72.99% to $3904.0 in 2023, then tumbled by 397.05% to -$11597.0 in 2024, then tumbled by 389.79% to -$56801.0 in 2025.
- The last three Depreciation Expense figures came in at -$56801.0 (Q4 2025), $95821.0 (Q3 2025), and $72533.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Sunshine Biopharma | 11.70 Mn | 4.79 Mn | 2.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -56,801.00 |
| Sep 30, 2025 | 95,821.00 |
| Jun 30, 2025 | 72,533.00 |
| Mar 31, 2025 | 64,793.00 |
| Dec 31, 2024 | -11,597.00 |
| Sep 30, 2024 | 64,627.00 |
| Jun 30, 2024 | 50,870.00 |
| Mar 31, 2024 | 42,618.00 |
| Dec 31, 2023 | 3,904.00 |
| Sep 30, 2023 | 37,210.00 |
| Jun 30, 2023 | 34,877.00 |
| Dec 31, 2022 | 14,455.00 |
| Sep 30, 2022 | 789.00 |
| Jun 30, 2022 | 2,287.00 |
| Mar 31, 2022 | 3,110.00 |
| Dec 31, 2021 | 3,184.00 |
| Sep 30, 2021 | 3,183.00 |
| Jun 30, 2021 | 3,192.00 |
| Mar 31, 2021 | 3,182.00 |
| Dec 31, 2020 | 3,540.00 |